Delta N p73 Antibody (38C674): sc-56086

ΔN p73 Antibody (38C674) is a mouse monoclonal IgG1 antibody designed to detect the ΔN p73 isoform, also known as Np73, in human, mouse, and rat samples using western blotting (WB). ΔN p73 monoclonal antibody (38C674) targets an epitope within amino acids 2-13 of the ΔN p73 protein, ensuring selective recognition without cross-reactivity with the full-length p73 isoform. ΔN p73 is an N-terminally truncated variant of the TP73 protein, a member of the p53 family of transcription factors that play a critical role in regulating cell cycle progression and apoptosis. Unlike the full-length TAp73, ΔN p73 lacks the transactivation domain and acts as a dominant-negative inhibitor of both wild-type p53 and TAp73, interfering with tumor suppressor functions. This inhibitory action is significant in cancer, as ΔN p73 is frequently overexpressed in various malignancies, contributing to tumor growth and drug resistance by preventing apoptosis and promoting cell survival. Within the cell, ΔN p73 is primarily localized in the nucleus, where ΔN p73 can interact with other transcription factors and regulatory proteins to modulate gene expression crucial for cell fate decisions. Understanding the localization and function of ΔN p73 is essential for elucidating its role in oncogenesis and for developing targeted cancer therapies. ΔN p73 (38C674) monoclonal antibody is an invaluable tool for researchers studying the molecular mechanisms of cancer progression and the intricate balance between pro- and anti-apoptotic signals mediated by p73 isoforms. By facilitating accurate detection and quantification of ΔN p73, anti-ΔN p73 antibody (38C674) supports advancements in cancer diagnostics and the development of novel therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Delta N p73 Antibody (38C674) References:

1. p73 in apoptosis.  |  Stiewe, T. and Pützer, BM. 2001. Apoptosis. 6: 447-52. PMID: 11595834
2. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript.  |  Pützer, BM., et al. 2003. Cell Death Differ. 10: 612-4. PMID: 12728260
3. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia.  |  Rizzo, MG., et al. 2004. Leukemia. 18: 1804-9. PMID: 15385938
4. deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation.  |  Mainardi, S., et al. 2007. Cell Death Differ. 14: 1968-71. PMID: 17690711
5. p73 in Cancer.  |  Rufini, A., et al. 2011. Genes Cancer. 2: 491-502. PMID: 21779517
6. Structure and apoptotic function of p73.  |  Yoon, MK., et al. 2015. BMB Rep. 48: 81-90. PMID: 25441426
7. p73-Governed miRNA Networks: Translating Bioinformatics Approaches to Therapeutic Solutions for Cancer Metastasis.  |  Logotheti, S., et al. 2019. Methods Mol Biol. 1912: 33-52. PMID: 30635889
8. p73 as a Tissue Architect.  |  Maeso-Alonso, L., et al. 2021. Front Cell Dev Biol. 9: 716957. PMID: 34368167
9. P63 and P73 Activation in Cancers with p53 Mutation.  |  Cai, BH., et al. 2022. Biomedicines. 10: PMID: 35884795
10. Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary Disease.  |  Richmond, BW., et al. 2024. Am J Respir Crit Care Med. 209: 153-163. PMID: 37931077

The preferred p73 antibody is p73 Antibody (E-4): sc-17823.